Calculating The Intrinsic Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Does the February share price for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by taking the expected future cash flows and discounting them to their present value. I will be using the Discounted Cash Flows (DCF) model. It may sound complicated, but actually it is quite simple! Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. If you are reading this and its not February 2019 then I highly recommend you check out the latest calculation for Eagle Pharmaceuticals by following the link below.

View our latest analysis for Eagle Pharmaceuticals

The method

I use what is known as a 2-stage model, which simply means we have two different periods of varying growth rates for the company’s cash flows. Generally the first stage is higher growth, and the second stage is a more stable growth phase. To start off with we need to estimate the next five years of cash flows. For this I used the consensus of the analysts covering the stock, as you can see below. I then discount the sum of these cash flows to arrive at a present value estimate.

5-year cash flow forecast

2019 2020 2021 2022 2023
Levered FCF ($, Millions) $76.60 $81.30 $79.70 $77.60 $90.02
Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Est @ 16%, capped from 48.26%
Present Value Discounted @ 13.66% $67.40 $62.94 $54.28 $46.50 $47.46

Present Value of 5-year Cash Flow (PVCF)= US$279m

After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.7%. We discount this to today’s value at a cost of equity of 13.7%.

Terminal Value (TV) = FCF2023 × (1 + g) ÷ (r – g) = US$90m × (1 + 2.7%) ÷ (13.7% – 2.7%) = US$846m

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$846m ÷ ( 1 + 13.7%)5 = US$446m

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is US$725m. To get the intrinsic value per share, we divide this by the total number of shares outstanding, or the equivalent number if this is a depositary receipt or ADR. This results in an intrinsic value of $48.6. Compared to the current share price of $41.05, the stock is about right, perhaps slightly undervalued at a 16% discount to what it is available for right now.

NASDAQGM:EGRX Intrinsic Value Export February 7th 19
NASDAQGM:EGRX Intrinsic Value Export February 7th 19

Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Eagle Pharmaceuticals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13.7%, which is based on a levered beta of 1.503. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. For EGRX, I’ve put together three essential aspects you should further examine:

  1. Financial Health: Does EGRX have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does EGRX’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of EGRX? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow for every stock on the NASDAQ every 6 hours. If you want to find the calculation for other stocks just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.